AI Article Synopsis
- FGFR4 is a receptor tyrosine kinase with a polymorphism (Gly388Arg) that may influence cancer risk.
- A meta-analysis of 27 studies showed that this polymorphism is linked to an increased cancer risk, particularly for breast and prostate cancers, while showing a reduced risk for lung cancer.
- The findings suggest that the FGFR4 polymorphism could be useful as a potential target for chemotherapy or a biomarker for identifying individuals at high risk for certain cancers.
Article Abstract
Fibroblast growth factor receptor 4 (FGFR4) is a member of receptor tyrosine kinase family. A functional Gly388Arg (rs351855 G>A) polymorphism in FGFR4 gene causes a glycine-to-arginine change at codon 388 within the transmembrane domain of the receptor. Although the FGFR4 rs351855 G>A polymorphism has been implicated in cancer development, its association with cancer risk remains controversial. Here, we have systematically analyzed the association between the rs351855 G>A polymorphism and cancer risk by performing a meta-analysis of 27 studies consisting of 8,682 cases and 9,731 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association. The rs351855 G>A polymorphism was associated with an increased cancer risk under the recessive model (OR=1.19, 95% CI=1.01-1.41). Stratified analysis by cancer type indicated the rs351855 G>A polymorphism was associated with an increased risk of breast and prostate cancer, but a decreased risk of lung cancer. This meta-analysis demonstrates the FGFR rs351855 G>A polymorphism is associated with increased cancer risk and suggests it could potentially serve as a chemotherapeutic target or biomarker to screen high-risk individuals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421931 | PMC |
| http://dx.doi.org/10.18632/oncotarget.15811 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: The aim: Evaluating the role SNP rs351855 of (FGFR4) gene and estimating the serum concentration of Visfatin cytokine and (HMGB-1) protein in AC patients and in healthy control blood samples.
Patients And Methods: Materials and methods: Blood samples were collected from 35 patients and 35 healthy controls, and then the serum was used for ELISA test, another each 2 ml blood were used for DNA extraction and rs351855 of (FGFR4) PCR assay.
Results: Results: there was no significant difference in mean HMG and mean visfatin among (FGFR4) rs351855 genotypes in patients and control group.
FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan.
Int J Environ Res Public Health
August 2020
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Fibroblast growth factor receptor 4 ( is involved in multiple physiological and pathological processes. Several genetic variants of have been shown to be associated with tumor progression in many cancers. However, its association, such as genetic variants and expression levels, with lung cancer is controversial.
View Article and Find Full Text PDFInvolvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma.
Int J Environ Res Public Health
December 2019
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Fibroblast growth factor receptor 4 (FGFR4) plays a prominent role in cell proliferation and cancer progression. This study explored the effect of FGFR4 single-nucleotide polymorphisms (SNPs) on the clinicopathological characteristics of urothelial cell carcinoma (UCC). This study was conducted to survey the possible correlation of the polymorphism of FGFR4 to the risk and clinicopathologic characteristics of UCC.
View Article and Find Full Text PDFSTAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.
J Clin Invest
May 2018
Max Planck Institute of Biochemistry, Department of Molecular Biology, Martinsried, Germany.
Immune evasion and the suppression of antitumor responses during cancer progression are considered hallmarks of cancer and are typically attributed to tumor-derived factors. Although the molecular basis for the crosstalk between tumor and immune cells is an area of active investigation, whether host-specific germline variants can dictate immunosuppressive mechanisms has remained a challenge to address. A commonly occurring germline mutation (c.
View Article and Find Full Text PDFFunctional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.
Oncotarget
April 2017
Molecular Epidemiology Laboratory and Department of Laboratory Medicine, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang, China.
Article Synopsis
- FGFR4 is a receptor tyrosine kinase with a polymorphism (Gly388Arg) that may influence cancer risk.
- A meta-analysis of 27 studies showed that this polymorphism is linked to an increased cancer risk, particularly for breast and prostate cancers, while showing a reduced risk for lung cancer.
- The findings suggest that the FGFR4 polymorphism could be useful as a potential target for chemotherapy or a biomarker for identifying individuals at high risk for certain cancers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!